Tapimmune Retains ROI Group as Investor Relations Counsel

VANCOUVER, BC – January 16, 2008 — TapImmune Inc. (OTC BB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced it has retained ROI Group LLC as investor relations counsel. “TapImmune is rapidly moving forward on managements strategies to take our therapeutic TAP vaccine into…

Details

TapImmune Inc. Announces Granting of U.S. Pat. Appln No. 10/046,542 Petition to Revive and Secures Bridge Financing

VANCOUVER, Canada, – TapImmune Inc., (OTCBB: TPIM) (the “Company”) a biotechnology specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced the USPTO has granted its petition to revive the U.S. Pat. Appln No. 10/046,542. This is a key patent application for the Company, as it describes a preferable delivery…

Details

TapImmune Inc. Announces Initiation of Testing on Novel Cancer Vaccine FDA Registered Facility Begins Testing on Company’s Lead Product

VANCOUVER, Canada,– TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced FDA compliant testing company AppTec, headquartered in St. Paul, Minnesota, has begun preclinical testing of its lead product, a TAP based therapeutic cancer vaccine. The immunotherapy vaccine is designed…

Details

TapImmune Inc. Announces Agreement with AppTec FDA Registered Facility to Begin Testing on Company’s Novel Cancer Vaccine

VANCOUVER, Canada,– TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced a contractual agreement with AppTec, headquartered in St. Paul, Minnesota, for the preclinical testing of its lead product. The immunotherapy vaccine is designed to treat a wide variety of…

Details

TapImmune Provides Operational Update including Human Data Supporting Use of TAP Based Cancer Vaccine Company Establishes Laboratory Facilities in Vancouver Canada

ANCOUVER, Canada, 31 July, 2007 – TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, opens new laboratory facilities and provides this update to shareholders. The opening of the new laboratory facility in Vancouver facilitates the transfer of its technology from The University of British Columbia…

Details

TapImmune Inc. Announces Acquisition of Core TAP Technologies and Intellectual Property from The University of British Columbia

New Name to Reflect a New Direction and Independent Operation VANCOUVER, BC – TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has fulfilled its financial obligation to The University of British Columbia for the proposed acquisition of its key…

Details